Comparison of the effects of enoxaparin and heparin on inflammatory biomarkers in patients with ST-segment elevated myocardial infarction: A prospective open label pilot clinical trial

Iranian Journal of Pharmaceutical Research

Volumn 13, Issue 2, 2014, Pages 583-590

  Nasiripour, Somayyeh ^a   Gholami, Kheirollah ^b   Mousavi, Sarah ^c   Mohagheghi, Abbas ^d   Radfar, Mania ^a   Abdollahi, Mohammad ^a   Khazaeipour, Zahra ^e   Mojtahedzadeh, Mojtaba ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute coronary syndrome; Enoxaparin; Heparin; Inflammatory biomarkers; STEMI

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FERRITIN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; MYELOPEROXIDASE; NITRIC ACID DERIVATIVE; SERUM AMYLOID A; STREPTOKINASE;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HEART EJECTION FRACTION; HEART RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; INTERNATIONAL NORMALIZED RATIO; LEUKOCYTE COUNT; MALE; MINERAL BLOOD LEVEL; OPEN STUDY; PARTIAL THROMBOPLASTIN TIME; PILOT STUDY; PROSPECTIVE STUDY; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE COUNT; UREA NITROGEN BLOOD LEVEL;

EID: 84902103293     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N. Engl. J. Med. (2005) 352: 1685-95.
2. Epstein FH, Fuster V, Badimon L, Badimon JJ and Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N. Engl. J. Med. (1992) 326: 242-50.
3. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation (2001) 104: 365-372.
4. Armstrong EJ, Morrow DA and Sabatine MS. Inflammatory biomarkers in acute coronary syndromes. Circulation (2006) 113: 152-155.
5. Lindahl B, Toss H, Siegbahn A, Venge P and Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N. Engl. J. Med. (2000) 343: 1139-147.
6. Kosuge M, Ebina T, Ishikawa T, Hibi K, Tsukahara K and Okuda J. Serum amyloid A is a better predictor of clinical outcomes than C-reactive protein in non-ST-segment elevation acute coronary syndromes. Circulation J. Off. J. Japanese Circulation Socie. (2007) 71: 186.
7. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH and Cannon CP. Serum amyloid A predicts early mortality in acute coronary syndromes: a TIMI 11A substudy. JACC. (2000) 35: 358-362.
8. Ikeda U, Ito T and Shimada K. Interleukin-6 and acute coronary syndrome. Clin. Cardiol. (2001) 24: 701-704.
9. Gil M, Zarȩbiński M and Adamus J. Plasma fbrinogen and troponin I in acute coronary syndrome and stable angina. Int. J. Cardiol. (2002) 83: 43-46.
10. Wang Y, Che S and Ma A. Clinical significance of serum cytokines IL-1beta, sIL-2R, IL-6, TNF-alpha, and IFN-v in acute coronary syndrome. Chinese med. Sci. J. (Chung-kuo i hsueh ko hsueh tsa chih)Chinese Academ. Med. Sci. (2004) 19: 120.
11. Morrow DA, Sabatine MS, Brennan ML, De Lemos JA, Murphy SA and Ruff CT. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur. Heart J. (2008) 29: 1096-1102.
12. Wollert KC, Kempf T, Peter T, Olofsson S, James S and Johnston N. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation (2007) 115: 962-971.
13. Ang Y, Mahmud N, White B, Byrne M, Kelly A and Lawler M. Randomized comparison of unfractionated heparin with corticosteroids in severe active infammatory bowel disease. Aliment. Pharmacol. Ther. (2000) 14: 1015-1022.
14. Baram D, Rashkovsky M, Hershkoviz R, Drucker I, Reshef T and Ben-Shitrit S. Inhibitory effects of low molecular weight heparin on mediator release by mast cells: preferential inhibition of cytokine production and mast cell-dependent cutaneous infammation. Clin. Exp. Immunol. (1997) 110: 485-491.
15. Bowler SD, Smith SM and Lavercombe PS. Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am. J. Respir. Crit Care. Med. (1993) 147: 160-163.
16. Carr J. The anti-infammatory action of heparin: Heparin as an antagonist to histamine, bradykinin and prostaglandin E1. Thromb. Res. (1979) 16: 507-516.
17. Ceyhan B and Çelikel T. Effect of inhaled heparin on methacholine-induced bronchial hyperreactivity. Chest. (1995) 107: 1009-1012.
18. Deepa P and Varalakshmi P. Favourable modulation of the infammatory changes in hypercholesterolemic atherogenesis by a low-molecular-weight heparin derivative. Int. J. Cardiol. (2006) 106: 338-347.
19. Diamant Z, Timmers MC, Van der Veen H, Page CP, Van der Meer F and Sterk PJ. Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma. Am. J. Respir. Crit Care. Med. (1996) 153: 1790-1795.
20. Downing LJ, Strieter RM, Kadell AM, Wilke CA, Greenfeld LJ and Wakefeld TW. Low-dose low- molecular-weight heparin is anti-inflammatory during venous thrombosis. J. Vasc. Surg. (1998) 28: 848-854.
21. Folwaczny C, Wiebecke B and Loeschke K. Unfractioned heparin in the therapy of patients with highly active infammatory bowel disease. Am. J. Gastroenterol. (1999) 94: 1551-1555.
22. Hochart H, Vincent Jenkins P, Smith OP and White B. Low-molecular weight and unfractionated heparins induce a downregulation of infammation: decreased levels of proinfammatory cytokines and nuclear factor-κB in LPS-stimulated human monocytes. Br. J. Haematol. (2006) 133: 62-67.
23. Lane DA and Adams L. Non-anticoagulant uses of heparin. N. Engl. J. Med. (1993) 329: 129-30.
24. Li J and Vlodavsky I. Heparin, heparan sulfate and heparanase in infammatory reactions. Thromb. Haemost. (2009) 102: 823-828.
25. Mousa SA (ed.) Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and infammation: emerging links 2007: New York: Stratton Intercontinental Medical Book Corporation, (1974).
26. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ and Bevilacqua MP. Heparin oligosaccharides bind L-and P-selectin and inhibit acute infammation. Blood (1993) 82: 3253-3258.
27. Rumelt S, Stolovich C, Segal ZI and Rehany U. Intraoperative enoxaparin minimizes infammatory reaction after pediatric cataract surgery. Am. J. Ophthalmol. (2006) 141: 433-437.
28. SalibaJr MJ. Heparin in the treatment of burns: a review. Burns (2001) 27: 349-358.
29. Zezos P, Papaioannou G, Nikolaidis N, Patsiaoura K, Papageorgiou A and Vassiliadis T. Low-molecular-weight heparin (enoxaparin) as adjuvant therapy in the treatment of active ulcerative colitis: a randomized, controlled, comparative study. Aliment. Pharmacol. Ther. (2006) 23: 1443-1453.
30. Wang L, Brown JR, Varki A and Esko JD. Heparins anti-infammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L-and P-selectins. J. Clin. Invest. (2002) 110: 127-136.
31. Montalescot G, Bal-dit-Sollier C, Chibedi D, Collet JP, Soulat T and Dalby M. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). Am. J. Cardiol. (2003) 91: 925-930.
32. Nallarantnam M MT, Kettle A, Smyth D, Winterbourn C, Elliott J, Richards M and McClean D. Heparin, But not bivalirudin, liberates endothelial myeloperoxidase in patients with ST Elevation Myocardial Infarction(STEMI). Heart Lung Circ. (2007) 16: 24-25.
33. Zairis MN, Adamopoulou EN, Manousakis SJ, Lyras AG, Bibis GP and Ampartzidou OS. The impact of hs C-reactive protein and other infammatory biomarkers on long-term cardiovascular mortality in patients with acute coronary syndromes. Atherosclerosis (2007) 194: 397-402.
34. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH and Elkind MSV. Criteria for evaluation of novel markers of cardiovascular risk: A Scientifc Statement From the American Heart Association. Circulation (2009)119: 2408-2416.
35. Jousilahti P, Salomaa V, Rasi V, Vahtera E and Palosuo T. The association of c-reactive protein, serum amyloid a and fbrinogen with prevalent coronary heart disease-baseline findings of the PAIS project. Atherosclerosis (2001) 156: 451-456.
36. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ and Sasiela WJ. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation (2003) 108: 1560-1566.
37. Koskenkari J, Kaukoranta P, Rimpiläinen J, Vainionpää V, Ohtonen P and Surcel HM. Anti-inflammatory effect of high-dose insulin treatment after urgent coronary revascularization surgery. Acta Anaesthesiologica Scandinavica. (2006) 50: 962-969.
38. Patti G, Grieco D, Dicuonzo G, Pasceri V, Nusca A and Di Sciascio G. High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention and Effects on Platelet Inhibition, Endothelial Function, and Infammation, Results of the ARMYDA-150 mg (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty) Randomized Study. JACC. (2011) 57: 771-778.
39. Elsayed E and Becker RC. The impact of heparin compounds on cellular infammatory responses: a construct for future investigation and pharmaceutical development. J. Thromb. Thrombolysis (2003) 15: 11-18.
40. Young E. The anti-inflammatory effects of heparin and related compounds. Thromb. Res. (2008) 122: 743-52.
41. Manduteanu I, Voinea M, Capraru M, Dragomir E and Simionescu M. A novel attribute of enoxaparin: inhibition of monocyte adhesion to endothelial cells by a mechanism involving cell adhesion molecules. Pharmacol. (2002) 65: 32-37.
42. Quartermain D, Li YS and Jonas S. The low molecular weight heparin enoxaparin reduces infarct size in a rat model of temporary focal ischemia. Cerebrovasc. Dis. (2003) 16: 346-55.
43. Vignoli A, Marchetti M, Balducci D, Barbui T and Falanga A. Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties. Haematologica. (2006) 91: 207-214.
44. James S. Coagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparin. Ups. J. Med. Sci. (2004) 109: 71-122.
45. Oldgren J, Fellenius C, Bomann K, Jansson JH, Nilsson TK, Wallentin L and Siegbahn A. Influence of prolonged dalteparin treatment on coagulation, fbrinolysis and inflammation in unstable coronary artery disease. J. Intern. Med. (2005) 258: 420-427.
46. Di Stefano R, Di Bello V, Barsotti MC, Grigoratos C, Armani C and Dell-Omodarme M. Inflammatory markers and cardiac function in acute coronary syndrome: difference in ST-segment elevation myocardial infarction (STEMI) and in non-STEMI models. Biomed. Pharmacother. (2009) 63: 773-780.
47. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP and Münzel T. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation (2003) 108: 1440-1445.
48. Dominguez-Rodriguez A, Samimi-Fard S, Abreu-Gonzalez P, Garcia-Gonzalez MJ and Kaski JC. Prognostic value of admission myeloperoxidase levels in patients with ST-segment elevation myocardial infarction and cardiogenic shock. Am. J. Cardiol. (2008) 101: 1537-1540.
49. Panahi Y, Mojtahedzadeh M, Zekeri N, Beiraghdar F, Khajavi MR and Ahmadi A. Metformin Treatment in Hyperglycemic Critically Ill Patients: Another Challenge on the Control of Adverse Outcomes. Iran. J. Pharm. Res. (2011) 10: 913-919.
50. Tabeefar H, Beigmohammadi MT, Javadi MR, Abdollahi M, Mahmoodpoor A and Ahmadi A. Effects of Pantoprazole on Systemic and Gastric Pro- and Anti-infammatory Cytokines in Critically Ill Patients. Iran. J. Pharm. Res. (2012) 11: 1051-108.
51. Dominguez-Rodriguez A, Abreu-Gonzalez P and Kaski JC. Diurnal variation of circulating myeloperoxidase levels in patients with ST-segment elevation myocardial infarction. Int. J. Cardiol. (2010) 144: 407-409.